Promin

Promin, or sodium glucosulfone, was a water-soluble sulfone drug developed and investigated during the first half of the twentieth century for infectious diseases including malaria, tuberculosis, and leprosy. It is a derivative of the sulfone class and is metabolized in the body to dapsone, which provides the principal therapeutic activity. Promin became historically important not because it remained a preferred medicine, but because it was among the first synthetic treatments to demonstrate meaningful activity against leprosy and other mycobacterial diseases. The compound’s origins are associated with early twentieth-century sulfone chemistry. Emil Fromm and J. Wittmann synthesized dapsone and related sulfone compounds, including Promin, in 1908 while conducting chemical research. Their work did not initially lead to clinical use, because the medical properties of these substances were not yet understood. A later synthesis at Parke, Davis & Co. in 1937 was sometimes treated as the drug’s point of origin, although the earlier Fromm–Wittmann work predates it. Interest in sulfones increased after synthetic sulfonamides demonstrated that chemically manufactured compounds could treat serious microbial infections. Early medical investigations of sulfone compounds were disappointing, but Promin and dapsone subsequently showed promise against diseases caused by mycobacteria. Promin appeared at first to offer a safety advantage over dapsone and was therefore studied in experimental tuberculosis models, including work at the Mayo Clinic using guinea pigs. Because tuberculosis and leprosy were both recognized as mycobacterial diseases, researchers considered whether the compound could also be applied to leprosy. Guy Henry Faget of the National Leprosarium in Carville, Louisiana, obtained information about Promin from Parke-Davis and learned of related animal research conducted by Edmund Cowdry at Washington University School of Medicine. Cowdry’s successful rat studies, published in 1941, encouraged Faget to begin human investigations. Initial trials involved six volunteers and were later expanded and repeated at other sites. Severe adverse effects temporarily halted the first studies, but subsequent work demonstrated that Promin could control leprosy. The results were reported internationally and represented a major therapeutic breakthrough. At a time when people with leprosy were commonly isolated, stigmatized, and restricted in everyday activities, the emergence of an effective treatment helped improve medical care and contributed to a reduction in the social stigma surrounding the disease. Promin had practical pharmaceutical characteristics that supported its early use. It was heat-stable and water-soluble, allowing it to be heat-sterilized and administered intravenously in ampules. These properties were useful in institutional and hospital settings, although intravenous administration was less convenient than oral therapy. Later clinical understanding showed that Promin offered no durable therapeutic advantage over the simpler compound dapsone. Because intolerance to dapsone generally reflects a broader sensitivity to sulfones, other sulfones could not reliably be substituted when dapsone caused adverse reactions. Modern multidrug treatment for leprosy relies principally on dapsone, rifampicin, and clofazimine, leaving Promin as a historical rather than current mainstream treatment.

Promin’s history combines early sulfone chemistry, interwar pharmaceutical development, and the emergence of effective chemotherapy for leprosy. The compound is also known as sodium glucosulfone. Its chemical lineage reaches back to work by Emil Fromm and J. Wittmann, who synthesized dapsone and related sulfone compounds, including Promin, in 1908. Their research was primarily chemical rather than clinical, and the medical potential of these compounds was not immediately explored. The later development of synthetic sulfonamides changed the scientific context. Their success against microbial disease encouraged researchers to reconsider other sulfur-containing compounds as possible anti-infective agents. Parke, Davis & Co. synthesized Promin in August 1937, and this event is sometimes credited as the compound’s discovery, although the earlier Fromm–Wittmann synthesis means that the historical attribution is more complex. Initial investigations of sulfones produced limited or disappointing results. Subsequent work, however, established that Promin and dapsone could act against important mycobacterial infections. Promin initially attracted interest because it appeared to be safer than dapsone. It was studied at the Mayo Clinic in a guinea-pig model of tuberculosis. Its relevance to leprosy became clearer because both tuberculosis and leprosy were understood to be caused by mycobacteria. Guy Henry Faget, working at the National Leprosarium in Carville, Louisiana, requested information about Promin from Parke-Davis. The company directed him to research by Edmund Cowdry at Washington University School of Medicine, where Promin had produced successful results in rats. Cowdry’s findings, published in 1941, provided the basis for human investigations. Faget began with six volunteers and later expanded and replicated the trials at other locations. The studies encountered severe side effects, leading to a temporary suspension of the initial testing. Continued research nevertheless showed that Promin was effective in controlling leprosy. The findings received worldwide attention. In practical terms, the treatment helped shift leprosy care away from a model defined almost entirely by isolation and institutional confinement. It also contributed to a reduction in the stigma attached to the disease and improved the prospects of patients who had previously faced severe social restrictions. Promin’s formulation offered operational benefits. It was stable when heated and soluble in water, which allowed heat sterilization and intravenous delivery in ampules. Those properties made it suitable for supervised treatment, but the medicine’s route of administration was burdensome. Later experience showed that Promin did not possess a meaningful advantage over dapsone, a simpler compound available in tablet form. Promin also could not serve as a dependable alternative for patients unable to tolerate dapsone, because adverse reactions often reflected sensitivity to the sulfone class rather than to dapsone alone. As leprosy treatment evolved, Promin lost its clinical prominence. Modern therapy uses multidrug regimens centered on dapsone, rifampicin, and clofazimine. Promin is therefore best understood as a historically significant pharmaceutical product: it helped establish that chemotherapy could control leprosy, but it is not a leading contemporary treatment.

• 1941

  Animal research supports leprosy studies

  [1]Prominen.wikipedia.org

  Edmund Cowdry’s published rat studies provided evidence that encouraged Guy Henry Faget to begin human investigations of Promin for leprosy.

• 1941

  Human leprosy trials begin

  [1]Prominen.wikipedia.org

  Faget initiated clinical studies, beginning with six volunteers and later expanding the work to additional locations.

• 1937

  Parke, Davis synthesis

  [1]Prominen.wikipedia.org

  Parke, Davis & Co. synthesized Promin in August 1937, an event sometimes cited as the drug’s discovery despite earlier chemical work.

• 1908

  Early synthesis of Promin-related sulfones

  [1]Prominen.wikipedia.org

  Emil Fromm and J. Wittmann synthesized dapsone and related sulfone compounds, including Promin, during chemical research.

• Promin becomes a historical leprosy treatment

  [1]Prominen.wikipedia.org

  Despite serious adverse effects during early testing, Promin demonstrated effectiveness and became an important early chemotherapy for leprosy.

A historical sulfone anti-infective whose principal significance was its early demonstrated effectiveness against leprosy and other mycobacterial diseases.

• Sulfone anti-infective

  Promin

  Promin, chemically known as sodium glucosulfone, was a heat-stable and water-soluble sulfone drug supplied in ampules for intravenous administration. It was investigated for malaria and tuberculosis and became historically notable for demonstrating useful activity against leprosy. The compound is converted in the body to dapsone, its therapeutically active form. Although initially considered potentially safer than dapsone, Promin later offered no important advantage over oral dapsone and is not part of the principal modern multidrug regimen for leprosy.

1. 1Prominen.wikipedia.org